Published in Neurology on May 08, 2013
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology (2015) 6.64
Overlapping demyelinating syndromes and anti–N-methyl-D-aspartate receptor encephalitis. Ann Neurol (2014) 3.40
The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol (2013) 3.13
Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler (2014) 1.56
Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol (2014) 1.38
Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm (2014) 1.29
AQP4 autoantibody assay performance in clinical laboratory service. Neurol Neuroimmunol Neuroinflamm (2014) 1.17
Demographic and clinical features of neuromyelitis optica: A review. Mult Scler (2015) 1.14
Update on biomarkers in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm (2015) 0.96
Seronegative NMO: a sensitive AQP4 antibody test clarifies clinical features and next challenges. Neurology (2013) 0.95
Aquaporin-4 autoantibodies in Neuromyelitis Optica: AQP4 isoform-dependent sensitivity and specificity. PLoS One (2013) 0.94
Aquaporin 4 IgG serostatus and outcome in recurrent longitudinally extensive transverse myelitis. JAMA Neurol (2014) 0.94
A clinical and radiological profile of neuromyelitis optica and spectrum disorders in an Indian cohort. Ann Indian Acad Neurol (2014) 0.88
Factors associated with the time to next attack in neuromyelitis optica: accelerated failure time models with random effects. PLoS One (2013) 0.86
Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus. Neurol Neuroimmunol Neuroinflamm (2016) 0.84
Central Nervous System Idiopathic Inflammatory Demyelinating Disorders in South Americans: A Descriptive, Multicenter, Cross-Sectional Study. PLoS One (2015) 0.84
CNS inflammation other than multiple sclerosis: how likely is diagnosis? Neurology (2014) 0.82
Neuromyelitis optica study model based on chronic infusion of autoantibodies in rat cerebrospinal fluid. J Neuroinflammation (2016) 0.81
Seronegative Neuromyelitis Optica: A Case Report of a Hispanic Male. Case Rep Neurol (2016) 0.79
Solitary sclerosis: Progressive neurological deficit from a spatially isolated demyelinating lesion: A further report. J Spinal Cord Med (2015) 0.78
Antibodies as Mediators of Brain Pathology. Trends Immunol (2015) 0.77
Mapping autoantigen epitopes: molecular insights into autoantibody-associated disorders of the nervous system. J Neuroinflammation (2016) 0.76
Finding NMO: The Evolving Diagnostic Criteria of Neuromyelitis Optica. J Neuroophthalmol (2016) 0.75
Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum. Ann Neurol (2016) 0.75
Neuromyelitis optica: an often forgotten cause of intractable nausea and vomiting. Case Rep Gastroenterol (2013) 0.75
Serological markers associated with neuromyelitis optica spectrum disorders in South India. Ann Indian Acad Neurol (2016) 0.75
Large-Scale in-House Cell-Based Assay for Evaluating the Serostatus in Patients with Neuromyelitis Optica Spectrum Disorder Based on New Diagnostic Criteria. J Clin Neurol (2017) 0.75
Differential diagnosis of neuromyelitis optica spectrum disorders. Ther Adv Neurol Disord (2017) 0.75
Neuromyelitis optica presenting as intractable vomiting and hyperCKaemia. J Neurol (2015) 0.75
Diagnostics of the neuromyelitis optica spectrum disorders (NMOSD). Neurol Sci (2017) 0.75
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med (2006) 6.25
Radiotherapy for glioblastoma in the elderly. N Engl J Med (2007) 5.64
Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med (2011) 4.93
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet (2012) 4.25
Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol (2008) 3.95
Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet (2012) 3.89
Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain (2003) 3.39
Natural history of multiple sclerosis: a unifying concept. Brain (2006) 2.96
Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol (2006) 2.80
Disrupted surface cross-talk between NMDA and Ephrin-B2 receptors in anti-NMDA encephalitis. Brain (2012) 2.39
Clinical specificities of adult male patients with NMDA receptor antibodies encephalitis. Neurology (2014) 2.38
Age at disability milestones in multiple sclerosis. Brain (2006) 2.37
Mutations in SPG11, encoding spatacsin, are a major cause of spastic paraplegia with thin corpus callosum. Nat Genet (2007) 2.17
Measuring the food environment using geographical information systems: a methodological review. Public Health Nutr (2010) 2.05
MRI monitoring of neuroinflammation in mouse focal ischemia. Stroke (2006) 1.91
Natural history of multiple sclerosis with childhood onset. N Engl J Med (2007) 1.89
Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol (2007) 1.88
A genome-scale DNA repair RNAi screen identifies SPG48 as a novel gene associated with hereditary spastic paraplegia. PLoS Biol (2010) 1.77
Krabbe disease in adults: phenotypic and genotypic update from a series of 11 cases and a review. J Inherit Metab Dis (2012) 1.71
Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain (2004) 1.70
Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option? Mult Scler (2013) 1.62
Long-term follow-up of acute partial transverse myelitis. Arch Neurol (2012) 1.50
Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers. Arch Neurol (2010) 1.49
Neuromyelitis optica and pregnancy. Neurology (2012) 1.49
First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability. J Pediatr (2004) 1.48
Collapsin response mediator proteins (CRMPs): involvement in nervous system development and adult neurodegenerative disorders. Mol Neurobiol (2003) 1.47
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol (2009) 1.46
Acute-onset chorea, dystonia, and cardiac fibroelastoma in a child: a paraneoplastic association? Mov Disord (2012) 1.44
Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury. Brain (2010) 1.42
Tear analysis in clinically isolated syndrome as new multiple sclerosis criterion. Mult Scler (2009) 1.41
Effects of anti-glutamic acid decarboxylase antibodies associated with neurological diseases. Ann Neurol (2007) 1.40
Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol (2006) 1.40
Paraneoplastic peripheral neuropathy associated with anti-Hu antibodies. A clinical and electrophysiological study of 20 patients. Brain (2002) 1.37
Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial. J Clin Oncol (2011) 1.34
In vivo effects of antibodies from patients with anti-NMDA receptor encephalitis: further evidence of synaptic glutamatergic dysfunction. Orphanet J Rare Dis (2010) 1.33
MRI prognostic factors for relapse after acute CNS inflammatory demyelination in childhood. Brain (2004) 1.31
Metabotropic glutamate receptor type 1 autoantibody-associated cerebellitis: a primary autoimmune disease? Arch Neurol (2010) 1.28
The pattern and diagnostic criteria of sensory neuronopathy: a case-control study. Brain (2009) 1.26
Regulation of spine development by semaphorin3A through cyclin-dependent kinase 5 phosphorylation of collapsin response mediator protein 1. J Neurosci (2007) 1.25
Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler (2013) 1.25
Prolonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomas. Neuro Oncol (2010) 1.24
Influence of pretreatment MRI parameters on clinical outcome, recanalization and infarct size in 49 stroke patients treated by intravenous tissue plasminogen activator. J Neurol Sci (2004) 1.24
Guillain-Barre syndrome, influenzalike illnesses, and influenza vaccination during seasons with and without circulating A/H1N1 viruses. Am J Epidemiol (2011) 1.21
A benign form of neuromyelitis optica: does it exist? Arch Neurol (2011) 1.21
Optical coherence tomography in neuromyelitis optica. Arch Neurol (2008) 1.20
Thrombolysis for ischemic stroke in patients with old microbleeds on pretreatment MRI. Cerebrovasc Dis (2004) 1.19
Factors influencing early admission in a French stroke unit. Stroke (2002) 1.16
New insights into cell responses involved in experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol Lett (2005) 1.15
Immunoglobulin G antibodies to the N-Methyl-D-aspartate receptor are distinct from immunoglobulin A and immunoglobulin M responses. Ann Neurol (2014) 1.13
NMO-IgG and Devic's neuromyelitis optica: a French experience. Mult Scler (2008) 1.12
Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility. Brain (2011) 1.11
Brain and bone damage in KARAP/DAP12 loss-of-function mice correlate with alterations in microglia and osteoclast lineages. Am J Pathol (2005) 1.11
Geographic variations of multiple sclerosis in France. Brain (2010) 1.10
One can prevent post-partum MS relapses by exclusive breast feeding: no. Mult Scler (2013) 1.09
Autoimmune limbic encephalopathy and anti-Hu antibodies in children without cancer. Neurology (2013) 1.07
Unusual monocular pendular nystagmus in multiple sclerosis. J Neuroophthalmol (2011) 1.06
Afferent facilitation of corticomotor responses is increased by IgGs of patients with NMDA-receptor antibodies. J Neurol (2010) 1.06
A tumor growth inhibition model for low-grade glioma treated with chemotherapy or radiotherapy. Clin Cancer Res (2012) 1.06
Peri-ictal pseudoprogression in patients with brain tumor. Neuro Oncol (2011) 1.06
Matrix-binding vascular endothelial growth factor (VEGF) isoforms guide granule cell migration in the cerebellum via VEGF receptor Flk1. J Neurosci (2010) 1.05
Regional variations in the prevalence of multiple sclerosis in French farmers. J Neurol Neurosurg Psychiatry (2007) 1.05
Collapsin response mediator protein 1 mediates reelin signaling in cortical neuronal migration. J Neurosci (2006) 1.04
Calpain product of WT-CRMP2 reduces the amount of surface NR2B NMDA receptor subunit. J Neurochem (2006) 1.03
Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. Mult Scler (2013) 1.03
Delayed onset of a second paraneoplastic neurological syndrome in eight patients. J Neurol Neurosurg Psychiatry (2010) 1.02
Differential expression of CRMP1, CRMP2A, CRMP2B, and CRMP5 in axons or dendrites of distinct neurons in the mouse brain. J Comp Neurol (2005) 1.02
Accumulation of irreversible disability in multiple sclerosis: from epidemiology to treatment. Clin Neurol Neurosurg (2006) 1.02
Surface dynamics of GluN2B-NMDA receptors controls plasticity of maturing glutamate synapses. EMBO J (2014) 1.02
An optimized immunohistochemistry technique improves NMO-IgG detection: study comparison with cell-based assays. PLoS One (2013) 1.01
Ethical issues of informed consent in acute stroke. Analysis of the modalities of consent in 56 patients enrolled in urgent therapeutic trials. Cerebrovasc Dis (2005) 1.01
Prognostic factors for progression of disability in the secondary progressive phase of multiple sclerosis. J Neurol Sci (2003) 1.00
Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. J Neurol Sci (2010) 0.99
Diffusion-weighted imaging in noncompressive myelopathies: a 33-patient prospective study. J Neurol (2010) 0.98
Uveitis associated with multiple sclerosis. Mult Scler (2008) 0.98